Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings

  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013
  Fourth Quarter Earnings

Business Wire

NEW YORK -- April 2, 2013

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and
marketer of pharmaceutical products, will release its Fiscal 2013 Fourth
Quarter financial results before the U.S. stock market opens on Tuesday, April
23, 2013. At 10:00 AM EDT, Forest will host a conference call where Elaine
Hochberg, Executive Vice President, Sales & Marketing and Chief Commercial
Officer, Frank Perier, Executive Vice President Finance & Administration and
Chief Financial Officer, and Dr. Marco Taglietti, Senior Vice President
Research & Development and President, Forest Research Institute, will discuss
the financial results and relevant company and industry topics.

The conference call will be webcast live beginning at 10:00 AM EDT on the
Company's website and also on the website
Please log on to either website at least fifteen minutes prior to the
conference call as it may be necessary to download software to access the
call. A replay of the conference call will be available until May 23, 2013at
both websites and also by dialing (855) 859-2056 (US and Canada) or (404)
537-3406 (international), Conference Call ID #32019672.

About Forest Laboratories

Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal,
and pain management medicine. The Company’s pipeline, the most robust in its
history, includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in New York, NY.
To learn more, visit

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.


Forest Laboratories, Inc.
Frank J. Murdolo
Vice President - Investor Relations
Press spacebar to pause and continue. Press esc to stop.